Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis

Rationale Dose equivalents based on dopamine D2 receptor occupancy can be used to compare antipsychotics on D2 receptor-mediated (adverse) effects such as extrapyramidal symptoms and altered emotionalexperiences. Previous meta-analyses modeling the dose-occupancy relationship hardly addressed potential heterogeneity of the imaging data. Objectives To model the relationship between dose and D2 receptor occupancy for a series of frequently prescribed antipsychotics while addressing the potential heterogeneity of the imaging data. Methods We conducted a meta-analysis on published D2 receptor occupancy data (positron emission tomography and single-photon emission computed tomography) in patients with schizophrenia treated with antipsychotics. A nonlinear mixed effects model estimated the median D2 receptor occupancy for a given antipsychotic dose. Heterogeneity between studies was investigated by incorporating study as a random effect in the model, in addition to patient- and study-specific explanatory variables. Results Included were 51 studies, describing 606 patients (mean ± SD age, 32.2 ±10.8 years; 25.7% female). The models described the dose-occupancy relationship with narrow confidence bands around the therapeuticdose range. Maximum occupancy (95% confidence interval[CI]) was estimated for haloperidol (91.9%; 95% CI, 86.1–97.8), risperidone(92.4%; 95% CI, 81.8–100), olanzapine (96.5%; 95% CI,85.8–100), clozapine (61.7%; 95% CI, 49.2–74.2), quetiapine (49.1%; 95% CI, 18.7–79.6), aripiprazole (86.9%; 95% CI, 78.2–95.7), ziprasidone (82.9%; 95% CI, 44.9–100), and amisulpride (85.0%; 95% CI, 68.5–100). Interindividual differences explained most of the variability in occupancy values, besides significant heterogeneity between studies. Conclusions Dose-occupancy functions estimated the median level of dopamine D2 receptor occupancy for 8 frequently prescribed antipsychotics in patients with schizophrenia. These dose equivalents can be used to compare antipsychotic effects in epidemiological studies and clinical practice.

[1]  Patrick Billingsley,et al.  Probability and Measure. , 1986 .

[2]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[3]  S. Kapur,et al.  The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study , 1997, Psychopharmacology.

[4]  Christer Halldin,et al.  Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.

[5]  S. Kapur,et al.  Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors—a PET study in schizophrenia , 2006, NeuroImage.

[6]  T. van Amelsvoort,et al.  Subjective Experience and Dopamine D2 Receptor Occupancy in Patients Treated with Antipsychotics: Clinical Implications , 2004 .

[7]  R. Mcquade,et al.  The Efficacy and Safety of Lower Doses of Aripiprazole for the Treatment of Patients with Acute Exacerbation of Schizophrenia , 2006, CNS Spectrums.

[8]  Organización Mundial de la Salud.  Guidelines for ATC classification and DDD assignment , 1996 .

[9]  David Taylor,et al.  Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. , 2009, CNS drugs.

[10]  D. Linszen,et al.  Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. , 2003, The American journal of psychiatry.

[11]  G. Nucci,et al.  Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients , 2008, Journal of psychopharmacology.

[12]  Alan A. Wilson,et al.  The D2 Receptor Occupancy Profile of Loxapine Determined Using PET , 1996, Neuropsychopharmacology.

[13]  H. Meltzer,et al.  In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. , 2008, Progress in brain research.

[14]  S. Kapur,et al.  Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. , 2001, The American journal of psychiatry.

[15]  J. Norris.  Appendix: probability and measure , 1997 .

[16]  D. Linszen,et al.  Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. , 2000, The American journal of psychiatry.

[17]  Lars Farde,et al.  Potentials and Pitfalls Using High Affinity Radioligands in PET and SPET Determinations on Regional Drug Induced D2 Receptor Occupancy—A Simulation Study Based on Experimental Data , 2001, NeuroImage.

[18]  F. Yasuno,et al.  Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. , 2004, The international journal of neuropsychopharmacology.

[19]  H. Jones,et al.  Dopamine and antipsychotic drug action revisited , 2002, British Journal of Psychiatry.

[20]  S. Kapur,et al.  High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. , 1996, The American journal of psychiatry.

[21]  C. Saller,et al.  Seroquel: biochemical profile of a potential atypical antipsychotic , 2005, Psychopharmacology.

[22]  R. Baldessarini,et al.  International consensus study of antipsychotic dosing. , 2010, The American journal of psychiatry.

[23]  D. Weinberger,et al.  59 NEUROCHEMICAL AND NEUROPHARMACOLOGICAL IMAGING IN SCHIZOPHRENIA , 2002 .

[24]  G. Sedvall,et al.  Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. , 1988, Archives of general psychiatry.

[25]  Jordi Llop,et al.  Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET , 2008, NeuroImage.

[26]  R. Bressan,et al.  Typical antipsychotic drugs — D2 receptor occupancy and depressive symptoms in schizophrenia , 2002, Schizophrenia Research.

[27]  A. Graff-Guerrero,et al.  Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs: A Systematic Review and Pooled Analysis , 2011, Journal of clinical psychopharmacology.

[28]  S. Kapur,et al.  Calculating Occupancy when One does not have Baseline: A Comparison of Different Options , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  R. Murray,et al.  D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients , 1994, British Journal of Psychiatry.

[30]  Christer Halldin,et al.  Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients , 1993, Biological Psychiatry.

[31]  P. Delespaul,et al.  Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. , 2011, The Journal of clinical psychiatry.

[32]  Alan A. Wilson,et al.  5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. , 1998, The American journal of psychiatry.

[33]  P. Seeman,et al.  Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors , 1998, Molecular Psychiatry.

[34]  R. M. Murray,et al.  Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia , 1992, The Lancet.

[35]  Iluminada Corripio,et al.  Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis , 2006, NeuroImage.

[36]  Tyrone D. Cannon,et al.  Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. , 2005, Archives of general psychiatry.

[37]  S. Leucht,et al.  Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs — An original patient data meta-analysis of the SPET and PET in vivo receptor imaging literature , 2008, Schizophrenia Research.

[38]  A. Graff-Guerrero,et al.  Dopamine D2 Receptor Occupancy and Clinical Effects: A Systematic Review and Pooled Analysis , 2011, Journal of clinical psychopharmacology.

[39]  John M. Davis,et al.  Dose Response and Dose Equivalence of Antipsychotics , 2004, Journal of clinical psychopharmacology.

[40]  Andrej Pázman,et al.  Nonlinear Regression , 2019, Handbook of Regression Analysis With Applications in R.

[41]  L. Farde,et al.  Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia , 2011, CNS neuroscience & therapeutics.

[42]  R. McGlinchey,et al.  Antipsychotics and Oropharyngeal Dysphagia in Hospitalized Older Patients , 2008, Journal of clinical psychopharmacology.

[43]  S. Kapur,et al.  A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. , 2000, Archives of general psychiatry.

[44]  N. Andreasen,et al.  Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs , 2010, Biological Psychiatry.

[45]  Alan A. Wilson,et al.  The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. , 1995, Life sciences.

[46]  S. Kapur,et al.  Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring , 2009, Acta psychiatrica Scandinavica.

[47]  Vincent J. Cunningham,et al.  Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings , 2003, NeuroImage.

[48]  Norman James,et al.  Practice guidelines for the treatment of psychiatric disorders , 2001 .

[49]  G. Frankle.  Neuroreceptor Imaging Studies in Schizophrenia , 2007, Harvard review of psychiatry.

[50]  R. Greef,et al.  Dopamine D2 Occupancy as a Biomarker for Antipsychotics: Quantifying the Relationship with Efficacy and Extrapyramidal Symptoms , 2011, The AAPS Journal.

[51]  G. Remington,et al.  Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls. , 2014, Journal of clinical psychopharmacology.